Roche Prothena News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Global Parkinson s Disease Drug Forecast Report 2021-2029, Featuring Teva, Roche, Prothena, UCB, AbbVie and Norvartis April 27, 2021 06:28 ET | Source: Research and Markets Research and Markets Dublin, IRELAND ResearchAndMarkets.com s offering. The global PD market is forecast to experience significant growth during the forecast period; global sales are expected to increase from $3.5B in 2019 to $11.5B in 2029, at a Compound Annual Growth Rate (CAGR) of 12.6%. This growth will be driven by the launch of 17 late-stage pipeline products. The highest selling drugs are expected to be: Roche/Prothena s PRX-002 followed by Novo Nordisk s Victoza. PRX-002 is a mAb with disease-modifying properties. KOLs were optimistic about this drug and suggested it may revolutionize PD treatment. Also, the MOA of Victoza was highly regarded as a potential neuroprotective drug in addition to its established high safety profile.

Neurocrine biosciencesWintec pharmaRoche prothenaNovo nordisk victozaEli lillyAmneal pharmaceuticalsBritannia pharmaceuticalsDevelopment of novelOrion pharmaceuticalsAcorda therapeuticsAnavex life sciencesNovo nordiskDrug forecastMarket analysisCompound annual growth rateTopics covered